Clinical Trial Search

Primary: Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hrs (AUC 0-24hr) of Raltegravir Following Once Daily Administration of Raltegravir — 53.7; 14.8; 46.3…

Primary: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Sampling Time Point (AUC0-t) of [14C]-Pimasertib Following Intravenous (IV) Administration on…

Primary: Percentage of Participants Who Have at Least 1 Treatment-Emergent Adverse Event (TEAE) for Part 1 — 83.3; 33.3; 100.0 percentage of participants

Primary: Cmax: Maximum Observed Plasma Concentration for TAK-648 — 4.504; 4.707; 5.185 mg/mL

Primary: Bioequivalence of the Free Base Variant of Selumetinib (Treatment B) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib Cmax] — 1330; 124 nanograms per…

Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) — 4; 8; 10; 0 Participants

Primary: Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Plasma Concentration (AUClast) of Oseltamivir and Oseltamivir Carboxylate on Day 1…

Primary: The Amounts of Radioactivity Excreted in Urine and Faeces — 78.0; 6.08; 84.1 percentage of administered dose

Primary: Pharmacokinetics - Cmax (ng/mL) — 394.7; 322.8 ng/mL

Primary: Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban — 293.994; 287.164 ng/mL

Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) as Measured by Activated Partial Thromboplastin Time (aPTT) Clotting Assay — 2888.9; 2646.3…

Primary: Change in Short Moods and Feelings Questionnaire (SMFQ) — 2.19; 1.21 units on a scale — p=<0.05

Primary: Maximum Observed Serum Concentration (Cmax) of Belatacept — 3.9; 6.2; 8.5; 11.1 ug/mL

Primary: 6 Minute Walk Test (6MWT) — 189; 172; 211; 170 meters — p=<0.25

Primary: Sex Without a Condom as Assessed by Self-report — 26; 24 participants